Condition
Androgen-insensitive Prostate Cancer
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results33% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00629057Phase 1CompletedPrimary
A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer
NCT01450683Phase 2Terminated
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
NCT01020305Phase 1Terminated
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Showing all 3 trials